Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke | SCAI

CLOSE was a multicenter randomized controlled trial conducted in France. Subjects with prior stroke and PFO were randomized to PFO closure with any CE-marked PFO device, antiplatelet therapy (aspirin, clopidogrel, or aspirin + dipyridamole), or anticoagulation (warfarin or a direct oral anticoagulant). At a mean of 3.2 years of follow-up, the PFO group had a lower rate of recurrent stroke; outcomes in the antiplatelet and anticoagulant groups were equivalent. Anatomic PFO features associated with elevated stroke risk were identified: atrial septal aneurysm and large shunt.

All Editors: Andrew M. Goldsweig, MD, MSC, RPVI, FSCAI

Integrated Search Topics